Tocilizumab: A Role for Biomarker-Directed Therapy?

Crit Care Med. 2022 Mar 1;50(3):510-513. doi: 10.1097/CCM.0000000000005281.

Authors

Jeffrey R Strich^{1

2}, Daniel S Chertow^{1

2

3}

Affiliations

¹ Department of Critical Care Medicine, National Institutes of Health Clinical Center, Bethesda, MD.
² United States Public Health Service Commissioned Corps, Rockville, MD.
³ Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.

No abstract available

Publication types

Editorial
Comment

MeSH terms

Antibodies, Monoclonal, Humanized* / therapeutic use
Biomarkers

Substances

Antibodies, Monoclonal, Humanized
Biomarkers
tocilizumab

Grants and funding

Z99 CL999999/ImNIH/Intramural NIH HHS/United States